These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Jones K; Felmingham D; Ridgway G Drugs Exp Clin Res; 1988; 14(10):613-5. PubMed ID: 2854515 [TBL] [Abstract][Full Text] [Related]
5. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Hoge CW; Gambel JM; Srijan A; Pitarangsi C; Echeverria P Clin Infect Dis; 1998 Feb; 26(2):341-5. PubMed ID: 9502453 [TBL] [Abstract][Full Text] [Related]
6. Role of azithromycin against clinical isolates of family enterobacteriaceae: A comparison of its minimum inhibitory concentration by three different methods. Chayani N; Tiwari S; Sarangi G; Mallick B; Mohapatra A; Paty BP; Das P Indian J Med Microbiol; 2009; 27(2):107-10. PubMed ID: 19384031 [TBL] [Abstract][Full Text] [Related]
7. Azithromycin: an interim analysis. Ball AP J Int Med Res; 1991; 19(6):446-50. PubMed ID: 1663467 [TBL] [Abstract][Full Text] [Related]
8. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Retsema J; Girard A; Schelkly W; Manousos M; Anderson M; Bright G; Borovoy R; Brennan L; Mason R Antimicrob Agents Chemother; 1987 Dec; 31(12):1939-47. PubMed ID: 2449865 [TBL] [Abstract][Full Text] [Related]
12. Lack of emergence of significant resistance in vitro and in vivo to the new azalide antibiotic azithromycin. Retsema JA; Girard AE; Brennan LA; Cimochowski CR; Faiella JA Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):843-6. PubMed ID: 1662628 [TBL] [Abstract][Full Text] [Related]
13. Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran. Aminshahidi M; Arastehfar A; Pouladfar G; Arman E; Fani F Microb Drug Resist; 2017 Dec; 23(8):1037-1044. PubMed ID: 29106325 [TBL] [Abstract][Full Text] [Related]
14. In-vitro concentration of azithromycin in human phagocytic cells. Panteix G; Guillaumond B; Harf R; Desbos A; Sapin V; Leclercq M; Perrin-Fayolle M J Antimicrob Chemother; 1993 Jun; 31 Suppl E():1-4. PubMed ID: 8396080 [TBL] [Abstract][Full Text] [Related]
15. Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):494-7. PubMed ID: 11561807 [TBL] [Abstract][Full Text] [Related]
16. Synergistic Antimicrobial Activity of Colistin in Combination with Rifampin and Azithromycin against Escherichia coli Producing MCR-1. Li Y; Lin X; Yao X; Huang Y; Liu W; Ma T; Fang B Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224527 [TBL] [Abstract][Full Text] [Related]
17. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Berry V; Thorburn CE; Knott SJ; Woodnutt G Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Suyama N; Tomono K Antimicrob Agents Chemother; 1994 Apr; 38(4):790-8. PubMed ID: 8031048 [TBL] [Abstract][Full Text] [Related]
20. Erythromycin, clarithromycin, and azithromycin: are the differences real? Amsden GW Clin Ther; 1996; 18(1):56-72; discussion 55. PubMed ID: 8851453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]